Carlsmed, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $438.2M
- Price
- $16.05
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.73%
- Volume
- 263.7K
About
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Quick stats
Shares outstanding27.3M
Computed float9.7M
Float / shares35.4%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001794546
Websitehttps://www.carlsmed.com
AI Summary
AI-generated1/19
majorbullishearnings
Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
Carlsmed reported Q2 2026 revenue of $18.9 million, up 57% year-over-year, driven by a more than 60% increase in its trained surgeon user base and strong procedural volume.
Gross margin expanded 340 basis points to 76.8%, and the company raised its full-year 2026 revenue guidance to a range of $74 million to $78 million, up from the previous $72 million to $77 million range.
Management highlighted a finalized CMS ruling effective October 1, 2026, which provides favorable reimbursement for inpatient lumbar procedures, as a significant catalyst for future growth.